Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J


As we previously reported , on September 20, 2017, Pfizer filed an antitrust lawsuit against Johnson & Johnson in the U.S. District Court for the Eastern District of Pennsylvania alleging that J&J has engaged in an anticompetitive scheme to protect its Remicade product. On November 28, 2017, J&J filed a motion to dismiss Pfizer's complaint alleging that Pfizer did not plead facts "showing that [J&J]'s discounts and rebates, rather than Pfizer's own unwillingness to offer lower prices on [Pfizer's] Inflectra or bundled discounts on Pfizer's many profitable, billion-dollar products, are the cause of Inflectra' s alleged poor record to date."



from Biotech News